These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 8064701)
41. Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension. Modena MG; Rossi R; Muia N; Origliani G; Rombolà O; Molinari R G Ital Cardiol; 1998 Jun; 28(6):636-44. PubMed ID: 9672776 [TBL] [Abstract][Full Text] [Related]
42. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR Menopause; 2008; 15(1):94-7. PubMed ID: 17882008 [TBL] [Abstract][Full Text] [Related]
43. Skin contamination by oestradiol gel--a remarkable source of error in plasma oestradiol measurements during percutaneous hormone replacement therapy. Vihtamäki T; Luukkaala T; Tuimala R Maturitas; 2004 Aug; 48(4):347-53. PubMed ID: 15283926 [TBL] [Abstract][Full Text] [Related]
44. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Chu MC; Cosper P; Nakhuda GS; Lobo RA Fertil Steril; 2006 Dec; 86(6):1669-75. PubMed ID: 17074346 [TBL] [Abstract][Full Text] [Related]
46. Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women. Dunkin J; Rasgon N; Wagner-Steh K; David S; Altshuler L; Rapkin A Psychoneuroendocrinology; 2005 Apr; 30(3):284-96. PubMed ID: 15511602 [TBL] [Abstract][Full Text] [Related]
47. Effect of hormone replacement therapy on hemostatic variables in post-menopausal women. Al-Farra HM; Al-Fahoum SK; Tabbaa MA Saudi Med J; 2005 Dec; 26(12):1930-5. PubMed ID: 16380775 [TBL] [Abstract][Full Text] [Related]
48. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K Menopause; 2006; 13(1):130-8. PubMed ID: 16607109 [TBL] [Abstract][Full Text] [Related]
50. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Balfour JA; Heel RC Drugs; 1990 Oct; 40(4):561-82. PubMed ID: 2083514 [TBL] [Abstract][Full Text] [Related]
51. Transdermal estradiol and testosterone transfer in man: existence, models, and strategies for prevention. Busse KL; Maibach HI Skin Pharmacol Physiol; 2011; 24(2):57-66. PubMed ID: 21088452 [TBL] [Abstract][Full Text] [Related]
52. Can climacteric women self-adjust therapeutic estrogen doses using symptoms as markers? Vihtamäki T; Tuimala R Maturitas; 1998 Jan; 28(3):199-203. PubMed ID: 9571594 [TBL] [Abstract][Full Text] [Related]
53. An oestrogen patch for hormone replacement therapy. Drug Ther Bull; 1989 Nov; 27(24):93-5. PubMed ID: 2519318 [No Abstract] [Full Text] [Related]
54. Urinary excretion of relaxin after estradiol treatment of postmenopausal women. Lippert TH; Armbruster FP; Seeger H; Mueck AO; Zwirner M; Voelter W Clin Exp Obstet Gynecol; 1996; 23(2):65-9. PubMed ID: 8737615 [TBL] [Abstract][Full Text] [Related]
55. Estrogen therapy in Turner syndrome: does the type, dose and mode of delivery matter? Mauras N; Torres-Santiago L; Taboada M; Santen R Pediatr Endocrinol Rev; 2012 May; 9 Suppl 2():718-22. PubMed ID: 22946283 [TBL] [Abstract][Full Text] [Related]
56. Quality of life after the menopause: influence of hormonal replacement therapy. Limouzin-Lamothe MA; Mairon N; Joyce CR; Le Gal M Am J Obstet Gynecol; 1994 Feb; 170(2):618-24. PubMed ID: 7509570 [TBL] [Abstract][Full Text] [Related]